Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Pulmonary Pharmacology & Therapeutics
|
July 15, 2014
A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
Dennis Kelleher, Lee Tombs, Andrew Preece, et al.
Advances in Therapy
|
October 4, 2020
24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
David A Lipson, Ruby Birk, Noushin Brealey, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
August 1, 2015
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
Noushin Brealey, Ashutosh Gupta, Jessica Renaux, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
January 8, 2015
Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study
Rashmi Mehta, Kelly Hardes, Noushin Brealey, et al.
Clinical Therapeutics
|
June 21, 2014
Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study
Rashmi Mehta, Kelly Hardes, Dennis Kelleher, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
January 30, 2016
Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer
Rashmi Mehta, Mickael Montembault, Francis Warren, et al.
European Journal of Endocrinology
|
July 28, 2022
Inhaled glucocorticoid-induced metabolome changes in asthma
Peter Daley-Yates, Brian Keppler, Noushin Brealey, et al.
Respiratory Research
|
January 27, 2018
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
Peter R Bremner, Ruby Birk, Noushin Brealey, et al.
Pulmonary Pharmacology & Therapeutics
|
July 8, 2018
Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD
Dave Hassall, Noushin Brealey, Wayne Wright, et al.
British Journal of Clinical Pharmacology
|
June 3, 2020
Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression
Peter Daley-Yates, Noushin Brealey, Sebin Thomas, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Pulmonary Pharmacology & Therapeutics
|
July 15, 2014
A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
Dennis Kelleher, Lee Tombs, Andrew Preece, et al.
Advances in Therapy
|
October 4, 2020
24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
David A Lipson, Ruby Birk, Noushin Brealey, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
August 1, 2015
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
Noushin Brealey, Ashutosh Gupta, Jessica Renaux, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
January 8, 2015
Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study
Rashmi Mehta, Kelly Hardes, Noushin Brealey, et al.
Clinical Therapeutics
|
June 21, 2014
Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study
Rashmi Mehta, Kelly Hardes, Dennis Kelleher, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
January 30, 2016
Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer
Rashmi Mehta, Mickael Montembault, Francis Warren, et al.
European Journal of Endocrinology
|
July 28, 2022
Inhaled glucocorticoid-induced metabolome changes in asthma
Peter Daley-Yates, Brian Keppler, Noushin Brealey, et al.
Respiratory Research
|
January 27, 2018
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
Peter R Bremner, Ruby Birk, Noushin Brealey, et al.
Pulmonary Pharmacology & Therapeutics
|
July 8, 2018
Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD
Dave Hassall, Noushin Brealey, Wayne Wright, et al.
British Journal of Clinical Pharmacology
|
June 3, 2020
Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression
Peter Daley-Yates, Noushin Brealey, Sebin Thomas, et al.
Page
of 3